

# IBD THERAPIES & CLASICAL EIMS

	Peripheral arthritis	Axial arthropaty	Uveitis	Pyoderma gangrenosum	PSC
Mesalazine					
Sulfasalazine					
Azathioprine					
Mercaptopurine					
Methotrexate					
Infliximab					
Adalimumab	Although evidence supports the benefit of antiTNF on certain EIMS the best characterized are infliximab and adalimumab in this setting				
Golimumab					
Certolizumab					
Vedolizumab	Observational data shows improvement in some patients*				
Ustekinumab					
Risankizumab					
Mirikizumab					
Guselkumab					
Tofacitinib			Observational data shows improvement in some patients		
Filgotinib			As per JAK family?		
Upadacitinib			Observational data shows improvement in some patients		
Ozanimod					
Etrasimod					

- Useful
- Not useful
- Could be useful

Gordon H et al. Journal of Crohn's and Colitis, 2024, 18, 1–37  
Rogler G et al. Gastroenterology. 2021; 161(4): 1118–1132.

\*Be aware of certain EIMs running parallel to bowel inflammation. Improvements in these manifestations often mirror improvements in bowel inflammation, providing insight into the positive response to some drugs. It is important to note post-hoc studies on ustekinumab trials, showed no significant improvement on EIMs although observational data did.

